BioSpecifics Technologies Corp
BioSpecifics Technologies — Investor Presentation (April 2015)
24 slides from BioSpecifics Technologies's investor presentation, Apr 13, 2015
Slide 1: Innovators in the development & commercialization of injectable collagenase
Innovators in the development & commercialization of INJECTABLE COLLAGENASE a 7 BioSpecifics April 2015
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes “forward-ooking statements” within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are “forward-looking statements".
Slide 3: BioSpecifics is a profitable, commercial-stage biopharma company
BioSpecifics is a profitable, commercial-stage biopharma company receiving increasing revenues for sales of collagenase clostridium histolyticum or CCH (XIAFLEX®) by partner Endo. Future revenue growth opportunities emerging from commitment to clinical development of new indications for CCH.
Slide 4: Vast Potential of CCH
Vast Potential of CCH » First-in-class, minimally invasive nonsurgical treatment for conditions caused by collagen accumulation with limited current treatment options = BioSpecifics has positive clinical results in 12 indications: — Dupuytren’s contracture’ — Frozen shoulder — Scarred tendons Peyron
Slide 5: Auxilium Acquired by Endo International
Auxilium Acquired by Endo International As of January 29, 2015, Auxilium Pharmaceuticals, Inc. (Auxilium) is now a wholly-owned subsidiary of Endo International plc (Endo). = Cash and stock transaction for approximately $2.6B* ~ Endo stock value appreciated “20% from date of transaction announcement
Slide 6: Marketed Indications for XIAFLEX
Marketed Indications for XIAFLEX Impressive Revenue Growth Revenue-Generating Products Dupuytren’s Approved in the U.S., EU, Canada & Australia; under Contracture review in Japan Peyronie’s Disease Approved in the U.S. and EU (as of January 2015)
Slide 7: XIAFLEX for Dupuytren's Contracture
XIAFLEX for Dupuytren’s Contracture First and Only FDA- and EMA-Approved Nonsurgical Treatment » Collagen cord in hand causing one or more fingers to contract toward the palm; limits range of motion and Definition impairs quality of life 300K patients diagnosed annually in the U.S. » Treatment of up
Slide 8: XIAFLEX for Peyronie's Disease
XIAFLEX for Peyronie’s Disease Sobi Received Approval for XIAPEX in EU First and Only. FDA- and EMA-Approved Nonsurgical Treatment = Inelastic collagen causing penile curvature; penis can bend at 90° angle during erection in severe cases Definition & » Associated with pain with erection, penile shor
Slide 9: Peyronie's Disease Market in the U.S.
Peyronie’s Disease Market in the U. Commercial success of XIAFLEX for Peyronie’s disease in 2014 exceeded expectations but still room for further market penetration given total number of patients and surgeries performed 95K patients diagnosed with 2013; likely underdiagnosed Approximately 400 urolog
Slide 10: XIAFLEX Pipeline Programs
XIAFLEX Pipeline Programs Future Revenue-Generating Opportunities Frozen Shoulder Syndrome Cellulite Phase 2b to initiate by year-end 2015 *Human 7 . afore Complete enrollment in Phase 2 in 2Q15 focal Ela heat fecrae for fartbereevekomen *Uterine Positive Fibroids See Capsular Contracture [RACE aad
Slide 11: CCH for Frozen Shoulder Syndrome
CCH for Frozen Shoulder Syndrome Potential to be Only FDA Approved Nonsurgical Therapy Definition & Complications - Inflammation and thickening of shoulder capsule due to collagen - Limits range of motion of shoulder = Common available treatment options are often painful and can Potential to be requ
Slide 12: Phase 2b Study of CCH in Frozen Shoulder
Phase 2b Study of CCH in Frozen Shoulder Study Design * Double-blind, placebo-controlled study evaluating safety and efficacy in Stage 2 (frozen stage) unilateral idiopathic frozen shoulder Objective & Rationale ~ Phase 2b study based on positive, statistically significant results in Phase 2a study
Slide 13: Phase 2b Study Results of CCH in FSS
Phase 2b Study Results of CCH in FSS Next Trial Expected to Start Strong, similar drug effect for key measures including forward flexion, shoulder abduction, external and internal rotation across both Phase 2a and Phase 2b trials ~ Similar CCH patient improvement in pain seen across both trials = In
Slide 14: CCH for Cellulite
CCH for Cellulite Phase 2b Trial to Initiate by Year-End 2015 = Skin dimpling as a result of collagen fibrous septae, occurring mainly Definition on the buttocks, lower limbs, and abdomen peer Market Affects 598% of women (est) and rarelyinmen % (nes Cate rau py ceritiel ta be fret and only FO/aprro
Slide 15: CCH for Cellulite: Top-line Data from Phase 2a Study
CCH for Cellulite Top-line Data from Phase 2a Study Top-line Data from Phase 2a Study Mid and high level CCH doses demonstrated statistically significant improvement in cellulite across all endpoints 68% of mid and high dose groups reported being “Satisfied” or “Very Satisfied” with treatment * Well
Slide 16: CCH for Human Lipomas
CCH for Human Lipomas Phase 2 Opt-In Study Managed by BioSpecifics Definition ~ Encapsulated deposits of benign fatty tumors; detected as bulges under the skin SEEN 1 No EDAcapproved pharmaceutical therapies available Only Approved . . ; ior R feical therapy Surgery not practical for patients with m
Slide 17: Positive Phase 2 Clinical Trial Results
Positive Phase 2 Clinical Trial Results Reported in January 2014 Open label, dose escalation Phase 2 trial: “w Statistically significant (1p<0.0001) reduction in primary endpoint of visible surface area of lipoma as measured by caliper, combining all patients Patients in highest dose group (75% of c
Slide 18: CCH for Lipomas in Canines
CCH for Lipomas in Canines Endo Announced Interest in Further Development Key Complications Potential to be Only Approved Nonsurgical Therapy $500K Opt-In Payment to BioSpecifics Opt-In Based on Chien-804 Results + Lipomas can cause seriously restrict motion in older dogs + Surgery can be risky due
Slide 19: CCH for Uterine Fibroids
CCH for Uterine Fibroids Endo Announced Interest in Further Development Definition & Key Complications Potential to be Nonsurgical Therapy Option U.S. Market Opportunity Encouraging Preclinical Data Pain, decreased fertility, . L , miscarriage, heavy menstrual : bleeding and frequent urination (4 Pr
Slide 20: Endo Partnership for Development and Commercialization of CCH
Endo Partnership for Development and Commercialization of CCH >$52.7M Received to Date Future Payments Due to BioSpecifics from Endo Endo Opt-In Rights Milestone Payments. from Endo Partnerships $52.7M received in licensing, sublicensing, milestone, COGS, and royalty payments as of December 31, 2014
Slide 21: Corporate Highlights
Corporate Highlights Projected Revenue Growth from Higher Royalt = Vast opportunity for growth in revenues from XIAFLEX sales and approval of CCH in new indications = Strong IP portfolio — Long-term patent protection for injectable collagenase: » Dupuytren’s Contracture: XIAFLEX has Orphan Drug prot
Slide 22: Consistently Profitable Annually
Consistently Profitable Annually Full Year 2014 Financial Highlights (unaudited) For the quarter ended For the year ended 12/31/14 12/31/13 12/31/14 12/31/13 Cash and equivalents, and investments $21,961,252 $12,591,825 Income Statement Revenues $4,650,485 $4,072,110 $14,077,056 $14,467,240 Other in
Slide 23: Anticipated Upcoming Milestones
Anticipated Upcoming Milestones Upcoming Milestones * Human 5 eons QO Complete enrollment in Phase 2 placebo-controlled opt-in trial in 2Q15 * ‘Uterine s ee Q Refining development plan Peyronie’s . Deeeie O Anticipated launch and building of sales momentum in the EU Dupuytren’s . Contracture © Decis
Slide 24: Innovators in the development & commercialization of injectable collagenase
Innovators in the development & commercialization of INJECTABLE COLLAGENASE — eo. BioSpecifics April 2015
Biospecifics Technologies — Investor Presentation (April 2015) on 6ix